Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing

Gynecologic Oncology

Volumn 143, Issue 2, 2016, Pages 326-333

  Pedersen, Kine ^a   Burger, Emily A ^a,b   Sy, Stephen ^b   Kristiansen, Ivar S ^a   Kim, Jane J ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cervical intraepithelial neoplasia; Cost effectiveness; HPV testing; Human papillomavirus; Mass screening; Mathematical model

Indexed keywords

ARTICLE; CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPING TECHNIQUE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NORWAY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SECONDARY ANALYSIS; SIMULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; ADULT; AGED; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; HUMAN PAPILLOMAVIRUS DNA TEST; MIDDLE AGED; PROCEDURES; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX; UTERINE CERVIX DYSPLASIA;

ADULT; AGED; ATYPICAL SQUAMOUS CELLS OF THE CERVIX; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX; TRIAGE;

EID: 84995485487     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.08.231     Document Type: Article

References (37)

1. [1] zur Hausen, H., Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384:2 (2009), 260–265.
2. [2] Plummer, M., Schiffman, M., Castle, P.E., et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 195:11 (2007), 1582–1589.
3. [3] Schiffman, M., Castle, P.E., Jeronimo, J., et al. Human papillomavirus and cervical cancer. Lancet 370:9590 (2007), 890–907.
4. [4] International Agency for Research on Cancer, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 100B. 2012, Agency for Research on Cancer, Lyon, France.
5. [5] Arbyn, M., Ronco, G., Anttila, A., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:Suppl. 5 (2012), F88–F99.
6. [6] NHS Cervical Screening Programme, HPV Primary Screening Pilot Announced. 2012 Accessed at www.cancerscreening.nhs.uk/cervical/nes/021.html on June 16, 2015.
7. [7] Vink, M.A., Bogaards, J.A., Meijer, C.J., et al. Primary human papillomavirus DNA screening for cervical cancer prevention: can the screening interval be safely extended?. Int J Cancer 137:2 (2015), 420–427.
8. [8] Nygard, M., Andreassen, T., Berland, J., et al. HPV testing in primary cervical cancer screening. 2013, The Norwegian Directorate of Health, Oslo, Norway Accessed at: http://kreftregisteret.no/Global/HPV-test%20i%20prim%c3%a6rscreening%20mot%20livmorhalskreft,%20Gruppe%20II.pdf on April 13, 2015.
9. [9] Nygard, M., Roysland, K., Campbell, S., et al. Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme. BMJ Open, 4(1), 2014, e003460.
10. [10] Castle, P.E., Sideri, M., Jeronimo, J., et al. Risk assessment to guide the prevention of cervical cancer. Am. J. Obstet. Gynecol. 197:4 (2007), 356.e1–356.e6.
11. [11] Jordan, J., Arbyn, M., Martin-Hirsch, P., et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 19:6 (2008), 342–354.
12. [12] Massad, L.S., Einstein, M.H., Huh, W.K., et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease 17:5 Suppl 1 (2013), 1–27.
13. [13] Arbyn, M., Anttila, A., Jordan, J., et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition–summary document. Ann. Oncol. 21:3 (2010), 448–458.
14. [14] Schiffman, M., Burk, R.D., Boyle, S., et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J. Clin. Microbiol. 53:1 (2015), 52–59.
15. [15] Burger, E.A., Ortendahl, J.D., Sy, S., et al. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br. J. Cancer 106:9 (2012), 1571–1578.
16. [16] Pedersen, K., Sørbye, S.W., Burger, E.A., et al. Using decision-analytic modeling to isolate interventions that are feasible, efficient and optimal: an application from the Norwegian cervical cancer screening program. Value Health 18:8 (2015), 1088–1097.
17. [17] Pedersen, K., Sørbye, S.W., Kristiansen, I.S., et al. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG: An International Journal of Obstetrics and Gynaecology, 2016, 10.1111/1471-0528.14135 Epub ahead of print.
18. [18] Mendes, D., Bains, I., Vanni, T., et al. Systematic review of model-based cervical screening evaluations. BMC Cancer, 15, 2015, 334.
19. [19] Kim, J.J., Wright, T.C., Goldie, S.J., Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287:18 (2002), 2382–2390.
20. [20] Campos, N.G., Burger, E.A., Sy, S., et al. An updated natural history model of cervical cancer: derivation of model parameters. Am. J. Epidemiol. 180:5 (2014), 545–555.
21. [21] Kim, J.J., Kuntz, K.M., Stout, N.K., et al. Multiparameter calibration of a natural history model of cervical cancer. Am. J. Epidemiol. 166:2 (2007), 137–150.
22. [22] Federal Reserve, Average rates of exchange. 2014 Accessed at: http://www.federalreserve.gov/releases/G5A/current/ on November 22, 2015.
23. [23] Norwegian Directorate of Health, Economic evaluation of health interventions - A guide. 2012 Accessed at: http://helsedirektoratet.no/publikasjoner/okonomisk-evaluering-av-helsetiltak–en-veileder/Publikasjoner/IS-1985.pdf on September 15, 2014.
24. [24] Norwegian Directorate of Health, Health Effects of Socio-economic Analyses. 2007, Norwegian Directorate of Health, Oslo, Norway Accessed at: https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/643/Helseeffekter-i-samfunnsokonomiske-analyser-IS-1435.pdf on August 15, 2015.
25. [25] Statistics Norway, 2015 Accessed at: https://www.ssb.no/nasjonalregnskap-og-konjunkturer/artikler-og-publikasjoner/norsk-okonomi-i-moderat-fart–180967?tabell=180881 on December 11, 2015.
26. [26] Technical Appendix. Harvard Cervical Cancer Natural History Model: Calibration and Costing Approach for Norway. Accessed at: http://www.med.uio.no/helsam/english/research/projects/preventive-strategies-hpv/harvardmodel-norway-technicalappendix.pdf on July 28, 2016.
27. [27] Cancer Registry of Norway, Annual Report of the Norwegian Cervical Cancer Screening Program, 2013–14. 2015, Cancer Registry of Norway, Oslo, Norway Accessed at: https://www.kreftregisteret.no/Generelt/Publikasjoner/Masseundersokelsen-mot-livmorhalskreft/Arsrapport-2013-2014/ on October 16, 2015.
28. [28] Pedersen, K., Burger, E.A., Campbell, S., et al. Risk of Cervical Cancer by Screening Intensity: A Registry-based Analysis. 2015, International Papillomavirus Conference, September 17–21, Lisbon, Portugal.
29. [29] Mayrand, M.H., Duarte-Franco, E., Rodrigues, I., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357:16 (2007), 1579–1588.
30. [30] Ronco, G., Dillner, J., Elfstrom, K.M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:9916 (2014), 524–532.
31. [31] Nanda, K., McCrory, D.C., Myers, E.R., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132:10 (2000), 810–819.
32. [32] Arbyn, M., Bergeron, C., Klinkhamer, P., et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet. Gynecol. 111:1 (2008), 167–177.
33. [33] Stoler, M.H., Ronnett, B.M., Joste, N.E., et al. The interpretive variability of cervical biopsies and its relationship to HPV status. Am. J. Surg. Pathol. 39:6 (2015), 729–736.
34. [34] Zappacosta, R., Gatta, D.M., Marinucci, P., et al. Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system. Expert. Rev. Mol. Diagn. 15:1 (2015), 137–150.
35. [35] Caro, J.J., Briggs, A.H., Siebert, U., et al. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force–1. Value in Health 15:6 (2012), 796–803.
36. [36] Burger, E.A., Sy, S., Nygard, M., et al. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS One, 9(3), 2014, e89974.
37. [37] Myers, E., Green, S., Lipkus, I., Patient preferences for health states related to HPV infection: visual analygue scales versus time trade-off eliciation [abstract]. 2004, Proceeding of the 21st International Papillomavirus Conference, Mexico City, Mexico.